The role of ligand shedding from tumor cells in the evasion of NK cell antitumor response and its clinical relevance have been shown for NKG2D (MICA/B, UL16-binding proteinsULBP-1,2), NKp30 (B7-H6, BAG6), DNAM1 (PVR-CD155) (Zhang et al., 2012; Schlecker et al., 2014; Iguchi-Manaka et al., 2016; Rusakiewicz et al., 2017; Zhao Y. et al., 2017; Molfetta et al., 2019; Table 1). The gene discussed is NCR3; the disease is neoplasm.